Pharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration

Basit Öğe Kaydı
dc.authoridCoskun, Devran/0000-0003-1151-1861
dc.contributor.authorCoskun, Devran
dc.contributor.authorCorum, Orhan
dc.contributor.authorCorum, Duygu Durna
dc.contributor.authorUney, Kamil
dc.date.accessioned2024-12-24T19:27:47Z
dc.date.available2024-12-24T19:27:47Z
dc.date.issued2023
dc.departmentSiirt Üniversitesi
dc.description.abstractObjective To determine the pharmacokinetics and bioavailability of meloxicam following intravenous (IV), intramuscular (IM), and oral administrations at a dose of 1.0 mg kg(-1) in Pekin ducks.Study design Randomized experimental trial.Animals A total of 18 clinically healthy male Pekin ducks.Methods Pekin ducks were randomly assigned to three groups of six ducks: IV, IM and oral. Meloxicam (1.0 mg kg(-1)) was administered to each Pekin duck. A non-compartmental analysis was used to evaluate pharmacokinetic parameters.Results No local or systemic adverse effects were observed in any bird. Meloxicam was detected in the plasma up to 120 hours following IV, IM or oral administration. The elimination half-life of the IV route was slightly shorter than that of the IM and oral routes (p < 0.05). Following IV administration, volume of distribution at steady state and total clearance were 133.17 mL kg(-1) and 6.68 mL kg(-1) hour(-1), respectively. The mean absorption time was 2.29 hours for IM and 1.13 hours for oral route. There were significant differences between IM and oral administration for the peak plasma concentration (C-max), time to reach C-max and bioavailability (p < 0.05).Conclusions and clinical relevance Meloxicam showed long elimination half-life and high bioavailability following IM and oral administration. Meloxicam in Pekin ducks provided the effective therapeutic concentration indicated in other species for up to 48 hours. However, there is a need to determine the clinical efficacy of meloxicam in Pekin ducks.
dc.identifier.doi10.1016/j.vaa.2023.07.007
dc.identifier.endpage484
dc.identifier.issn1467-2987
dc.identifier.issn1467-2995
dc.identifier.issue6
dc.identifier.pmid37620232
dc.identifier.scopus2-s2.0-85168581122
dc.identifier.scopusqualityQ1
dc.identifier.startpage477
dc.identifier.urihttps://doi.org/10.1016/j.vaa.2023.07.007
dc.identifier.urihttps://hdl.handle.net/20.500.12604/6798
dc.identifier.volume50
dc.identifier.wosWOS:001110200200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofVeterinary Anaesthesia and Analgesia
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241222
dc.subjectbioavailability
dc.subjectduck
dc.subjectmeloxicam
dc.subjectpharmacokinetics
dc.titlePharmacokinetics and bioavailability of meloxicam in Pekin ducks following intravenous, intramuscular and oral administration
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu